4.8 Review

Alzheimer's Disease: The Challenge of the Second Century

Journal

SCIENCE TRANSLATIONAL MEDICINE
Volume 3, Issue 77, Pages -

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.3002369

Keywords

-

Funding

  1. NIA NIH HHS [R37 AG013956-16, R01 AG016208, P50 AG005681, P01 AG003991, U01 AG032438-04, P01 AG026276-05, P01 AG003991-29, R01 AG035083, R01 AG016208-11, RC1 AG035654-02, R37 AG013956, RC1 AG035654, R01 AG035083-02, P01 AG026276, P50 AG005681-28, U01 AG032438] Funding Source: Medline

Ask authors/readers for more resources

Alzheimer's disease (AD) was first described a little more than 100 years ago. It is the most common cause of dementia with an estimated prevalence of 30 million people worldwide, a number that is expected to quadruple in 40 years. There currently is no effective treatment that delays the onset or slows the progression of AD. However, major scientific advances in the areas of genetics, biochemistry, cell biology, and neuroscience over the past 25 years have changed the way we think about AD. This review discusses some of the challenges to translating these basic molecular and cellular discoveries into clinical therapies. Current information suggests that if the disease is detected before the onset of overt symptoms, it is possible that treatments based on knowledge of underlying pathogenesis can and will be effective.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available